Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Cheung

Showing results (81-90 of 144) with videos related to

Pageof 15
Sort By:
Nature|February 15, 2023
Evidence for Dirac flat band superconductivity enabled by quantum geometryHaidong Tian, Xueshi Gao, Yuxin Zhang, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 25, 2016
Diagnosis, referral, and primary treatment decisions in newly diagnosed prostate cancer patients in a multidisciplinary diagnostic assessment programDavid Guy, Gabriella Ghanem, Andrew Loblaw, et al.
International Journal of Radiation Oncology, Biology, Physics|August 17, 2010
Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancerGerard C Morton, D Andrew Loblaw, Hans Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 20, 2011
Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?Gerard Morton, Andrew Loblaw, Patrick Cheung, et al.
The Lancet. Oncology|January 21, 2014
Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort studyRobert K Nam, Patrick Cheung, Sender Herschorn, et al.
The Lancet. Diabetes & Endocrinology|May 12, 2016
Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort studyChristopher J D Wallis, Kirk Lo, Yuna Lee, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 28, 2020
Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trialMark Corkum, Andrew Loblaw, Yaser Hasan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 9, 2020
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 GyGerard Morton, Merrylee McGuffin, Hans T Chung, et al.
International Journal of Radiation Oncology, Biology, Physics|May 12, 2018
Impact of Magnetic Resonance Imaging on Gross Tumor Volume Delineation in Non-spine Bony Metastasis Treated With Stereotactic Body Radiation TherapySrinivas Raman, Lee Chin, Darby Erler, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 9, 2016
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5GyGerard Morton, Hans T Chung, Merrylee McGuffin, et al.
Pageof 15

Showing results (81-90 of 144) with videos related to

Sort By:
Pageof 15
Nature|February 15, 2023
Evidence for Dirac flat band superconductivity enabled by quantum geometryHaidong Tian, Xueshi Gao, Yuxin Zhang, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 25, 2016
Diagnosis, referral, and primary treatment decisions in newly diagnosed prostate cancer patients in a multidisciplinary diagnostic assessment programDavid Guy, Gabriella Ghanem, Andrew Loblaw, et al.
International Journal of Radiation Oncology, Biology, Physics|August 17, 2010
Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancerGerard C Morton, D Andrew Loblaw, Hans Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 20, 2011
Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?Gerard Morton, Andrew Loblaw, Patrick Cheung, et al.
The Lancet. Oncology|January 21, 2014
Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort studyRobert K Nam, Patrick Cheung, Sender Herschorn, et al.
The Lancet. Diabetes & Endocrinology|May 12, 2016
Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort studyChristopher J D Wallis, Kirk Lo, Yuna Lee, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 28, 2020
Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trialMark Corkum, Andrew Loblaw, Yaser Hasan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 9, 2020
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 GyGerard Morton, Merrylee McGuffin, Hans T Chung, et al.
International Journal of Radiation Oncology, Biology, Physics|May 12, 2018
Impact of Magnetic Resonance Imaging on Gross Tumor Volume Delineation in Non-spine Bony Metastasis Treated With Stereotactic Body Radiation TherapySrinivas Raman, Lee Chin, Darby Erler, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 9, 2016
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5GyGerard Morton, Hans T Chung, Merrylee McGuffin, et al.
Pageof 15